May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 11, 2013, Pages 1955-1960

  Botticella, Angela ^a   Guarneri, Alessia ^a   Filippi, Andrea Riccardo ^a   Levra, Niccolo Giaj ^a   Munoz, Fernando ^a   Ragona, Riccardo ^a   Gontero, Paolo ^b   Ricardi, Umberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Non metastatic castration resistant prostate cancer (CRPC); Primary androgen deprivation therapy (ADT); Prostate adenocarcinoma; Rising prostate specific antigen (PSA); Salvage external beam radiotherapy (EBRT)

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; ANDROGEN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; RADIATION DOSE; REGIONAL METASTASIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY; METABOLISM; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDY; SALVAGE THERAPY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84892665349     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1520-3     Document Type: Article

References (17)

1. Akimoto T, Kitamoto Y, Saito J et al (2004) External beam radiotherapy for clinically node-negative, localized hormonerefractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes. Int J Radiat Oncol Biol Phys 59:372-379
2. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117-1123
3. Gogna NK, Baxi S, Hickey B et al (2012) Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormonerefractory prostate cancer. Int J Radiat Oncol Biol Phys 83:e205-e211
4. Guarneri A, Botticella A, Ragona R et al (2013) Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World J Urol 31:411-415
5. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61-71
6. Ko EC, Stone NN, Stock RG (2012) PSA nadir of \0.5 ng/mL following brachytherapy for early stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 83:600-607
7. Lankford SP, Pollack A, Zagars GK (1995) Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 33:907-912
8. Mohler JL, Armstrong AJ, Bahnson RR et al (2012) Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:1081-1087
9. Nakamura K, Teshima T, Takahashi Y et al (2004) Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer Res 24:3141-3146
10. Oefelein MG, Agarwal PK, Resnick MI (2004) Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 171:1525-1528
11. Ogawa K, Nakamura K, Sasaki T et al (2009) External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months. Int J Radiat Oncol Biol Phys 74:759-765
12. Ray ME, Thames HD, Levy LB et al (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64:40-50
13. Roach M III, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974
14. Sanguineti G, Marcenaro M, Franzone P et al (2004) Is there a ''Curative'' role of radiotherapy for clinically localized hormone refractory prostate cancer. Am J Clin Oncol 27:264-268
15. Sasaki T, Nakamura K, Ogawa K et al (2009) Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the patterns of care study in Japan. BJU Int 104:1462-1466
16. Shamash J, Davies A, Ansell W et al (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 98:22-24
17. Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate non metastatic prostate cancer. J Clin Oncol 23:2918-2925